Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.74 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.74 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4635941 | 0.99 | CHRM1 (0.72) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4636326 | 0.85 | CHRM1 (1.00) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| Hydrochloric Acid SCHEMBL4636433 | 0.84 | CHRM1 (0.98) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4939578 | 0.84 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL17758364 | 0.84 | CHRM1 (0.77) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| Hydrochloric Acid SCHEMBL4635781 | 0.83 | CHRM1 (0.69) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4637225 | 0.83 | CHRM1 (0.75) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4939715 | 0.83 | CHRM1 (0.75) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4939063 | 0.83 | CHRM1 (0.75) | CHRM1CHRM2CHRM4CHRM3CHRM5 | |
| SCHEMBL4636552 | 0.82 | CHRM1 (0.74) | CHRM1CHRM2CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | claimed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | claimed |
| EP-1937670-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | claimed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | claimed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1937670-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885CHRM2 2/4885CHRM4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.